Curia´s Patented Process for Intermediates Useful for Etrasimod Arginine
white paper
internal
In this white paper, we describe how Curia’s patented new process solves main prior art drawbacks by the provision of a simple, cost-effective and industrially applicable process for the preparation of enantiomeric substituted 2-(1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives such as etrasimod and to intermediates useful therefor. If you want to learn more, check the asset below or Curia’s patent application WO2026/022274.